These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285 [TBL] [Abstract][Full Text] [Related]
32. Adaptive mitochondrial reprogramming and resistance to PI3K therapy. Ghosh JC; Siegelin MD; Vaira V; Faversani A; Tavecchio M; Chae YC; Lisanti S; Rampini P; Giroda M; Caino MC; Seo JH; Kossenkov AV; Michalek RD; Schultz DC; Bosari S; Languino LR; Altieri DC J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25650317 [TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors. He Y; Li J; Koga T; Ma J; Dhawan S; Suzuki Y; Furnari F; Prabhu VV; Allen JE; Chen CC Neuro Oncol; 2021 Mar; 23(3):400-411. PubMed ID: 32830856 [TBL] [Abstract][Full Text] [Related]
34. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. Allen JE; Crowder RN; El-Deiry WS PLoS One; 2015; 10(11):e0143082. PubMed ID: 26580220 [TBL] [Abstract][Full Text] [Related]
35. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development. Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503 [TBL] [Abstract][Full Text] [Related]
36. Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth. Ranjan A; Wright S; Srivastava SK Oncotarget; 2017 Jul; 8(29):47632-47641. PubMed ID: 28512255 [TBL] [Abstract][Full Text] [Related]
37. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Allen JE; Prabhu VV; Talekar M; van den Heuvel AP; Lim B; Dicker DT; Fritz JL; Beck A; El-Deiry WS Cancer Res; 2015 Apr; 75(8):1668-74. PubMed ID: 25681273 [TBL] [Abstract][Full Text] [Related]
38. Mitochondria and cancer chemoresistance. Guerra F; Arbini AA; Moro L Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):686-699. PubMed ID: 28161329 [TBL] [Abstract][Full Text] [Related]
39. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of metabotropic glutamate receptor III facilitates sensitization to alkylating chemotherapeutics in glioblastoma. Maier JP; Ravi VM; Kueckelhaus J; Behringer SP; Garrelfs N; Will P; Sun N; von Ehr J; Goeldner JM; Pfeifer D; Follo M; Hannibal L; Walch AK; Hofmann UG; Beck J; Heiland DH; Schnell O; Joseph K Cell Death Dis; 2021 Jul; 12(8):723. PubMed ID: 34290229 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]